With 0.51 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.94 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $24.0 whereas the lowest price it dropped to was $20.145. The 52-week range on INKT shows that it touched its highest point at $76.00 and its lowest point at $4.56 during that stretch. It currently has a 1-year price target of $39.00. Beta for the stock currently stands at 0.34.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of INKT was down-trending over the past week, with a drop of -68.35%, but this was up by 171.16% over a month. Three-month performance surged to 159.39% while six-month performance rose 133.48%. The stock gained 191.43% in the past year, while it has gained 95.31% so far this year. A look at the trailing 12-month EPS for INKT yields -2.50 with Next year EPS estimates of -2.37. For the next quarter, that number is -0.55. This implies an EPS growth rate of 20.16% for this year and -3.94% for next year. EPS is expected to grow by 5.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 16.86%.
Float and Shares Shorts:
At present, 3.97 million INKT shares are outstanding with a float of 0.99 million shares on hand for trading. On 2025-06-13, short shares totaled 10657.0, which was 27.0 higher than short shares on 1747267200. In addition to Dr. Garo H. Armen Ph.D. as the firm’s Executive Chairman, Dr. Jennifer S. Buell Ph.D. serves as its President, CEO & Director.
Institutional Ownership:
Through their ownership of 0.015800001 of INKT’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, INKT reported revenue of $0.0 and operating income of -$2532765.0. The EBITDA in the recently reported quarter was -$2314078.0 and diluted EPS was -$0.7.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With INKT analysts setting a high price target of 70.0 and a low target of 35.0, the average target price over the next 12 months is 52.5. Based on these targets, INKT could surge 244.66% to reach the target high and rise by 72.33% to reach the target low. Reaching the average price target will result in a growth of 158.49% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.5802 being high and -$3.7128 being low. For INKT, this leads to a yearly average estimate of -$3.6465. Based on analyst estimates, the high estimate for the next quarter is -$0.32 and the low estimate is -$0.58. The average estimate for the next quarter is thus -$0.45.
